LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. ACN
3. FFAI
4. PAGP
5. WBD
6. FAN
7. COHR
8. NXE
9. STI
10. MCD

Go back to LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Merck & Co. (NYSE: MRK) Delayed: 146.87 --0 (-0%)
Previous Close $146.87    52 Week High $65.46 
Open $146.87    52 Week Low $47.97 
Day High $146.87    P/E 99.91 
Day Low $146.87    EPS $1.47 
Volume 7,646